{
    "nct_id": "NCT03665155",
    "official_title": "First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody",
    "inclusion_criteria": "* Age 21 years or greater\n* Histologically/Immunohistochemistry confirmed CD38-positive multiple myeloma\n* At least one tumor lesion on CT, MRI, or FDG PET/CT within 60 days of protocol enrollment\n* ECOG performance status 0 to 2\n* For Phase II patients only: plan for initiation of standard-of-care daratumumab/lenalidomide therapy.\nHealthy volunteers allowed\nMust have minimum age of 21 Years",
    "exclusion_criteria": "* Life expectancy < 3 months\n* Pregnancy or lactation\n* Patients who cannot undergo PET/CT scanning because of weight limits. PET/CT scanners may not be able to function with patients over 450 pounds.\n* History of anaphylactic reaction to humanized or human antibodies or a Grade 3 or 4 administration reaction during a daratumumab administration.",
    "miscellaneous_criteria": ""
}